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Summary: arProteinase inhibitor was purified from procine blood by ammonium sulphate and Cibachron
Blue-Sepharose fractionation, ion exchange chromatography on DEAE-Cellulose, gel filtration on Sephadex
G-25, and zinc chelating chromatography. Thus, an inhibitor preparation with a specific activity of 1.62
lU/mgprotein (enzyme: trypsin; Substrate: BzArgNan) was obtained. In sodium dodecyl sulphate gel electroph-
oresis one protein band corresponding to a molecular mass of 67.6 kDa was found. On isoelectric focusing
6 protein bands with isoelectric points of 3.80, 3.90, 4.05, 4.20, 4.25 and 4.45 were separated. The amino
acid composition was determined. The association rate constants for the Inhibition of various serine
proteinases were measured.
Isolierung und Charakterisierung des on-Proteinaseinhibitors des Schweins
Leukocyten-oLj-Proteinaseinhibitor-Komplexe in Schweineblut, L
Zusammenfassung; arProteinaseinhibitor wurde aus Schweineblut mittels Ammoniumsulfatfallung und Frak-
tionierung an Cibachron-Blau-Sepharose, lonenaustauschchromatographie an DEAE-Cellulose, Gelfiltration
an Sephadex G-25 und Zink-Chelat-Chromatographie isoliert. Die erhaltene Inhibitor-Präparation hatte eine
spezifische Aktivität von 1,62 ITJ/mg Protein (Enzym: Trypsin; Substrat: BzArgNan). In der Natriumdodecyl-
sulfat-Elektrophorese wurde eine Proteinbande mit einer dazugehörigen Molekülmasse von 67,6 kDa erhalten.
In der isoelektrischen Fokussierung wurden 6 Proteinbanden mit isoelektrischen Punkten von 3,80, 3,90,
4,05, 4,20, 4,25 und 4,45 gefunden. Die Aminosäurezusammensetzung wurde bestimmt. Die Assoziationskon-
stanten für die Hemmung von verschiedenen Serinproteinasen wurden gemessen.
Abbreviations:
BzArgNan:
. Na-benzQyl-L-arginine-p-nitrQanilide *
IEP:
Isoelectric point
IU:
Inhibitor linits (mlU = milMU)
kDa:
kilo-Dalton
/>ValLeuLysNan:
^-valyl-L-leucyl-L-lysine^-nitroanilide
Suc(Ala)3Nan:
MeOSuc(Ala)2PrQValNan:
N -methoxysuccmyl·(L-alanyl)2-L-p olyl-L-valine-/?-
nitroanilide
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TosGlyProArgNan:
Ne-tosyl-L-glycyl-L-prolyl-Z»-arginine-/7-nitroanilide
Suc(Ala)2ProPheNan:
Ne-succinyl-(L-alanyl)2-L-prolyl-L-phenyIalanine-p-
nitroanilide
(H2N2)2CNBzONp:
p-nitrophenyl /?'-guanidobenzoate
2) Enzymes:
porcine trypsin (EC 3.4.21.4), bovine chymotrypsin (EC
3.4.21.1), bovine thrombin (EC 3.4.21.5), boar acrosin (EC
3.4.21.10), bovine plasmin (EC 3.4.21.7), porcine pancreatic
elastase (EC 3.4.21.36), porcine leukocyte elastase (EC
3.4.21.37) from polymorphonuclear granulocytes.
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Bovine thrombin and chymotrypsin, bovine plasmin and Tos-
GlyProArgNan were from Boehringer Mannheim, Mannheim.
Boar acrosin was kindly provided by W. Müller-Ester l, Munich.
Porcine leukocyte elastase was isolated according to Geiger et
al.3).
Antiserum against porcine plasma was from Miles Laborato-
ries, Ltd., Frankfurt.
Cibachron-BIue-Sepharose was synthesized according to
Travis & Johnson (10).
Human a^-proteinase inhibitor was from Behringwerke AG,
Marburg/Lahn.
Suc(Ala)3Nan, MeOSuc(Ala)2ProvValNan and Suc(Ala)2
ProPheNan were from Novabiochem AG, Läufelfingen·, Swit-
zerland.
jDValLeuLysNan was a gift froni Kabi, Mölndal, Sweden.
Starting material
Porcine blood was collected from healthy pigs in the slaughter
house of Munich in bottles containing sodium citrate in a final
concentration of 3.8 g/l to prevent coagulation. The blood
samples were separated from blood cells by centrifugation
(1800g) for 30min and the supernatant plasma was used for
the Isolation of arproteinase inhibitor.
Preparation of the zinc chelate column
One hundred millilitres of chelating Sepharose 6B were washed
on a sintered glass filter (G3) using 1.51 dist. water. The
Sepharose was then added to a glass column (100 · l cm) and
loaded with zinc ions at 4 °C by pumping through 200 ml of
a zinc chloride solütion (5 g/l). Thereafter the column was
washed free of unbound zinc with distilled water and equili-
brated with 0.05 mol/1 phosphate buffef (Na2HPO4), pH 8.0,
containing 0.15 mol/1 soldium chloride.
Activity and Inhibi t ion irieäsurements
The activity and molarity of trypsin used for the determination
of the inhibitory activity of arproteinase inhibitor was meas-
ured by titration with (HjNj^CNBzONp according to Chase &
Shaw (10). Porcine trypsin used for the tests had an activity of
5.4 U/mg protein (Substrate: BzArgNan). Inhibitory activity of
di-proteinase inhibitor was measured äs described by Fritz et
al. (11). Porcine trypsin and BzArgNan were used in the assay.
The activities of chymotrypsin, thrombin, plasmin, acrosin,
pancreatic elastase and leukocyte elastase, and their Inhibition
by Qt-proteinase inhibitor were determined äs described form-
erly (13 — 17). Porcine leukocyte elastase activity was measured
using the following procedure (wavelength: 405nm; 25°C; vol-
ume: l ml; = 1020 m2 · mol-1; (30)): 0.98 ml 2.14 mmpl/1
MeOSuc(Ala)2ProValNan in 0.1 mol/1 HEPES bufTer, pH 7.5,
containing 0.5 mol/1 sodium chloride were incubated at 25 °C
for 5 min. Thereafter 0.02 ml elastase solütion was added and
the increase in absorbance per minute was read for 5 minutes.
Association rate constants were measured and calculated ac-
cording to Beatty, Bieth & Travis (18).
Electrophoresis
Coomassie RTM Blue G (Serva, Heidelberg, FRG) was used
for protein staining.
Polyacrylamide gel electrophoresis in the presence of sodium
3) Geiger, R., Junk, A. & Jochum, M., this Journal in prepa- dodecyl sulphate was performed according to Weber & Osborne
ration ' (19).
Introduction
,-Proteinase inhibitor, formerly called arantitryp-
sin, is a glycoprotein and responsible for more than
90% of the trypsin and elastase inhibiting capacity
of plasma or serum (1). The high concentration of
this inhibitor in blood, interstitial fluid and mucous
secretions and its broad inhibitory specificity towards
proteinases (2, 3) reflects an important role in regulat-
ing physiological and/or preventing pathological pro-
cesses in the organism.
In this connection, the pathological events of major
interest are inflammatory processes (4) and bacterial
sepsis with its most serious complication, septic
shock. As demonstrated recently, arproteinase inhib-
itor complexes with and thereby inhibits lysosömal
elastase, which is liberated by endotoxin-induced
mechanisms from polymorphonuclear granulocytes
(4).
Furthermore, it has been shown that an increase of
the plasma levels of the elastase-dj-proteinase inhibi-
tor complex in humans, äs determined by enzyme
immunoassay (5), is an early indication of the inflam-
matory response in septicaemia (6), multiple trauma
(7) and rheumatoid arthritis (8). In view of the poten-
tial significance of the elastase-ai-proteinase inhibitor
complex for the diagnosis of severe infections (6, 8)
äs well äs for monitoring of the therapeutic effective-
ness of inhibitors of lysosömal proteinases (9) devel-
opment of suitable experimental animal models
would be highly desirable. We have therefore isolated
porcine arproteinase inhibitor and porcine leukocyte
elastase3) for the development of an elastase-inhibitor
immunoassay, which permits the quantitation of lyso-
sömal elastase liberation from pig polymorpho-
nuclear granulocytes.
In this communication the purification of porcine
arproteinase inhibitor is described and a detailed
characterization of the purified inhibitor is given.
Materials and Methods
DEAE-Cellulose (DE-52) was from Whatman Chemicals, Clif-
ton, U. S. A.
Sephadex G-75 and chelating Sepharose were from Pharmacia
Fine Chemicals AB, Uppsala, Sweden.
BzArgNan, porcine trypsin and porcine pancreatic elastase
were from Merck, Darmstadt.
Ampholine® 2—11 and ampholine 2 — 6 were from LKB,
Bromma, Sweden.
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arProteinase inhibitor was submitted to electrpfocusing in po-
lyacrylamide gels (t = 50 g/l, C = 30 g/l, containing 60 ml/l
Ampholine® 2-11, or 60 ml/l Ampholine® 2-6) according to
Righetti & Drysdale (20).
Isoelectric point Standards from Serva (Heidelberg, FRG) were
used äs markers.
Immunoelectrophoresis and rocket immunoelectrophoresis
were performed äs described in l, c. (21).
Molecular mass determinat ions
Molecular mass determinations were performed by polyacryl-
amide gel electrophoresis. Molecular mass Standards from Bio-
Rad (Richmond, California) were used äs markers.
Protein determination
Protein concentration was determined according to Polin &
Ciocalteau (22), and by quantitative amino acid analysis. For
protein determination according to Polin & Ciocalteau, human
ctrproteinase inhibitor served äs a reference Standard.
Amino acid analysis
For amino acid analysis samples were hydrolysed in vacuo at
110 °C with 5.7 mol/1 HC1 for 24 h and analysed with a Durrum
D 500. The N-terminal amino acid residues were determined
by Edman degradation (23). The phenylthiohydantoins were
identified by an isocratic high performance liquid chromatogra-
phy System (34).
Results
Isolation procedure
Purification of arproteinase inhibitor from porcine
blood was achieved by the following procedure
(tab. 1).
Step l
One litre of porcine citrate plasma was fractionated
at room temperature with ammonium sulphate. The
precipitate obtained between 0.50 and 0.80 Saturation
was dissolved in 0.03 mol/1 phosphate buffer
(Na2HPO4), pH 6.7 and the solution dialysed for 24 h
at 4 °C with several changes of the same buffer.
Step 2
The dialysed solution (640 ml) was applied at room
temperature to a Cibachron-Blue-Sepharose column
(100-5 cm) equilibrated with phosphate buffer (0.03
mol/1 Na2HPO4) pH 6.7. The flow rate was 100 ml/h.
The column was then washed with phosphate buffer,
and 9 ml fractions were collected. The fractions con-
taining arproteinase inhibitor were eluted in the void
volume, whereas porcine serum albumin remained
tightly bound to the dye. The Cibachron-Blue Se-
pharose column was regenerated first with 0.5 mol/1
KSCN and subsequently by equilibration with 0.03
mol/1 phosphate buffer pH 6.7.
Step 3
The <xrproteinase inhibitor-containing fractions from
step 2 were combined (1020 ml) and the pH was
shifted to pH 6.5 by addition of 2 mol/1 HC1. The
solution was applied at a rate of 30 ml/h at room
temperature to a DEAE-cellulose column (30 · 2.5
cm; DE-52, Whatman Chemicals) equilibrated with
phosphate buffer (0.03 mol/1 Na2HPO4) pH 6.5.
Thereafter the column was washed with buffer until
the eluate was free of protein (A2so < 0.005). <xr
Proteinase inhibitor was eluted with a linear gradient
of NaCl (0-0.2 mol/1) in phosphate buffer at the
same flow rate. The gradient was formed from 1100
ml phosphate solution and 1100 ml sodium Chloride
solution. Fractions of 10 ml were collected (fig. 1).
Tab. 1. Purification of porcine ccrproteinase inhibitor. The data represent mean values of three different preparations.
Step
•
1
2
3
4
5
Procedure and eluate therefrom
•
Porcine citrate plasma
Ammonium sulphate fractionation
(after dialysis)
Cibachron-blüe Sepharose
DEAE-cellulose
Sephadex G-75
Zinc chelate column
Volume
(ml)
1000
640
1020
205
180
22
Total
protein
(mg)a
53500
14970
5783
346
270
16.7
Total
inhibitory
activity
IUb
1610.0
494.3
429.4
241.8
239.6
27.0
Specific
inhibitory
activity
lU/mg
0.030
0.033
0.074
0.699
0.887
1.616
Puri-
fication
factor
1
1.1
2.5
23.3
29.6
53.9
* Protein concentfation was determined according to Polin & Ciocalteau (23).b
 Inhibitory activity of ocrproteinase inhibitor was determined with trypsin and BzArgNan äs Substrate, cf. Methods.
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Fig. 1. Gradient elution chromatography ofthe ctpproteinase inhibitor-contaimng fractiqns from Step 2 (cf. tab. 1) on DEAE-
cellulose. Experimental details are given in Results. otrproteinase inhibitor inhibitory activity was measured by Inhibition
of porcine trypsin in the BzArgNan assay (o—o), protein concentration is given ais absorbance at 280 nm (—.—-—), the
concentration ofthe NaCl gradient is indicated ( ).
Step 4
The most active fractions from the preceding Step
were pooled (205ml) and concentrated by ultrafil-
tration (Amicon membrane YM 10). Thereafter the
buffer was changed by repeated Ultrafiltration to 0.05
mol/1 phophate buffer (Na2HPO4) pH 8.0 containing
0.15 mol/1 NaCl. The resulting solution was applied
at a rate of 11 ml/h to a Sephadex G-75 column (100
• 5 cm) equilibrated with the same phosphate buffer.
1.0-
§0.5
J—l T" l ι Ι ι ι
100 200
Fraction no.
J l ι ι ι ι L
400
300 =
§
100-1
300
Fig. 2. Fractionation of porcine arproteinase inhibitor from
step 4 (cf. Tabl. 1) on zinc chelate Sepharose. Experi-
mental details are given in Results. at-Proteinase inhibi-
tor was assayed by inhibition of porcine trypsin in the
BzArgNan assay (e-o), protein concentration is given
s absorbance at 280 nm ( ). Phosphate buffer
(0.05 mol/1, pH 6.5, containing 0.15 mol/1 NaCl) is used
from the Start for elution.
Fractions were combined and concentrated by ultra-
filtration (Amicon membrane YM 10).
Step 5
The arproteinase inhibitor solution from step 4 (180
ml) was applied to a zinc chelate column (100 -
l cm) equilibrated with 0.05 mol/1 phosphate b ffer
(Na2HPO4) pH 8.0 containing 0.15 mol/1 NaCl. ar
Proteinase inhibitor was eluted s shown in figure 2
with 0.05 mol/1 phosphafe buffer pH 6.5 containing
0.15 mol/1 NaCl. Fractions were collected in 1.5 ml
portions at a flow rate of 7.5 ml/h.
The arproteinase inhibitor solution was divided into
small portions and stored frozen at —20 °C. At this
temperature the inhibitor was stable for more than
12 months.
200ΪΞ Chemical and physical characteristics
Electrophoresis
In polyacrylamide gel electrophoresis containing so-
dium dodecyl sulphate only one protein band appe-
ared that corresponded to a molecular mass of 67.6
kDa (fig. 3).
On electrofocusing of arproteinase inhibitor s mples
in carrier ampholytes (pH gradient from 2 to 11)
several protein bands were found in positions round
pH 4 (fig. 4 a and b). Using a carrier ampholyte
gradient froin 2 to 6, six protein bands with isoelectric
points of 3.80, 3.90, 4.05, 4.20, 4.25, and 4.45 were
found (fig. 4c and d).
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Mr
— 116000
— 97400
— 68000
— 64000
— 31000
— 21500
— 14400
terminal amino acid residues. After one Edman
degradation cycle, the phenylthiohydantoin deriva-
tives of amino acids were identified by high perform-
ance liquid chromatography. After application of a
sufficient amount of <xrproteinase inhibitor (10 nmol)
to the degradation cycle, no residue could be ident-
ified at all by HPLC (detection limit: 0.015 nmol).
This result suggests that the amino terminal sequence
of porcine arproteinase inhibitor, like that of human
aj-proteinase inhibitor (25), Starts with a glutamic
acid residue, and that this glutamic residue is con-
verted into pyroglutamic acid during the isolation
procedure, which is a well known phenomenon.
A B
Fig. 3. Sodium dodecyl sulphate gel electrophoresis of porcine
α,-proteinase inhibitor (20 μ§; gel A). For experimentai
details and MT determination, see Methods. Molecular
mass Standards are present in gel B.
PH
4.85—'
5,65—l
5,92 ^ _.
6.05 """i
6.45—.
6.80 —
7.30 — l
7.75—'
8.30 —
10.60 —!
PH
2.80 —
3.50 —
3.75 —
4.15 —
4.55 —
5.20—'
5.85
6.55—
PH
— 3.80
— 3.90
— 4.05
— 4.20
— 4.25
— 4.45
A B
Fig. 4, Isoelectric focusing pf porcine arproteinase inhibitor.
A, protein Standards (IEP from 4.85 to 10.6); B and D,
10 μg of porcine arprpteinase inhibitor each; C, protein
Standards (IEP from 2.80 to 6.55). Isoelectric focusing
was performed in amphplme 2 to 11 (A and B) and
ampholine 2 to 6 (C and P). For details, see Methods.
N-terminal residue
Homogeneity of the arproteinase inhibitor prepa-
ration was checked further by analysis of the N-
Amino acid composition
The amino acid composition calculated from analyses
of 3 Durrum runs and based on a molecular mass of
67.6 kDa was determined. The data are listed in
table 2 together with those of human arproteinase
inhibitor for comparison.
Tab. 2. Amino acid compositions of human and porcine α,-
proteinase inhibilor. The given values represent mol of
residues per mol inhibitor.
Amino acid
Asp
Thr
Ser
Glu
Pro
Gly
Ala
Cys
Val
Met
Ile
Leu
Tyr
Phe
His
Lys
Arg
Trp
arProteinase
Porcinea
52
38
42
54
25
47
30
n.d.
11
8
20
48
10
12
8
40
14
n.d.b
inhibitor
Human (9, 27)
49
25
23
54
22
24
24
1
27
8
18
50
9
28
13
39
7
1
a
 Extrapolated to hydrolysis time zero.
b
 Without tryptophan (n/d.: not detectable).
Stability
The inhibitor obtained by the given isolation proce-
dure was stable in sodium chloride solution (9 g/l) at
-20 °C for more than 12 months. At 4 °C no loss of
inhibitory activity was observed for several months.
To prevent bacterial growth and loss of activity due
to bacterial proteinases, 2 g/l of sodium azide should
be added to the solution kept at 4 °C.
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Tab. 3. Association rale constants kass for Ihc interaction of porcine α,-proteinase inhibitor with various proteinases (25 °C, pH
8.0) mcasured and calculatcd according to Beatty et al. (19).
Enzyme
Trypsin, porcine
Chymotrypsin, bovine
Thrombin, bovine
Plasmin, bovine
Acrosin, boar
Pancreatic elastasc, porcine
Leukocyte elastasc, porcine
Final
concentration
100 nmol/I
9 nmol/1
1 1 μΐΉθΙ/1
0.83 μηιοΐ/ΐ
75 nmol/1
20 nrnol/1
50 nmol/1
Substrate
BzArgNan
Suc(Ala)2ProPheNan
TosGlyProArgNan
DValLeuLysNan
BzArgNan
Suc(Ala)3Nan
MeOSuc(Ala)2ProValNan
Final
concentration
0.8 mmol/1
0.5 mmol/1
0.7 mmol/1
0.6 mmol/1
0.8 mmol/1
1 mmol/1
1 mmol/1
kass
(1 χ mol-1
1.8 χ 104
1.5 χ 106
1.1 χ 102·
6.7 χ 102
3.2 χ 104
9.3 χ 104
1.1 χ 106
χ s-1)
Kinetic properties
For the Inhibition of porcine trypsin by porcine ar
proteinase inhibitor a specific inhibitory activity of
1.62 lU/mg was obtained. The association rate con-
stants obtained for the Inhibition of various serine
proteinases by arproteinase inhibitor are summa-
rized in tabje 3.
Immunological properties
In immunoelectrophoresis of arproteinase inhibitor
with porcine plasma for comparison, and in rocket
immunoelectrophoresis (fig. 5), arproteinase inhibi-
tor proved to be homogeneous.
A B C
Fig. 5. Rocket immunoelectrophoresis of arproteinase inhibi-
tor. The agarose gel contained 2% (v/v) rabbit antiserum
against whole porcine serum. Immunoelectrophoresis
was done at 80 V and 10 m A for 16 h in 0.1 mol/1 sodium
barbital, pH 8.6.
arproteinase inhibitor concentrations: A, 5 μg; B, 2.5
μgand C, 1.25 μg.
Discussion
Human arproteinase inhibitor has attracted the
interest of biochemists, molecular and cell biologists,
scientists engaged in genetics s well s clinicians for
many years (for reviews, see 1. c. 3, 9, 26, 27). It is
surprising, therefore, that only recently methods haVe
been published for the relatively rapid Isolation of
pure human arproteinase inhibitor in native and
stable form (28). We used a combination of the vari-
ous Steps described formerly for the purification of
porcine arproteinase inhibitor which, to our best
Knowledge, has not previously been obtained in
homogeneous form. In addition to the removal of
albumin, which is present in appreciable amounts in
commercially available human arproteinase inhibitor
samples, the final Step of chromatography on zinc
chelate-Sepharose under mild conditions (28) proved
most efficaceous for producing a highly active and
stable preparation (cf. ta£, l and Results).
The described purification protocol enabled us to
isolate porcine arproteinase inhibitor in a degree
of purity close to 99%, s judged by the following
analyses:
(i) Sodium dodecylsulphate electroph resis showed
only one band with the expected molecular mass
(fig. 3).
(ii) In isoelectric focusing all protein bands assembled
around pH 4 (fig. 4) s in the case of human ar
proteinase inhibitor (27). This microheterogeneity of
arproteinase inhibitor is well known and at least
partly due to differences in the carbohydrate chains,
especially in the sialic acid content of the inhibitor
molecules (10).
(iii) Amino terminal end group analysis by a very
sensitive and sophisticated quantitative method failed
to detect any amino acid in an amount corresponding
(on a molar basis) to more than 1% of the applied
arproteinase inhibitor preparation. This could be
explained by the presence of;glutamic acid in the
J. Clin. Chem. Clin. Biochem../ Vol. 23, 1985 / No. 10
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native molecule, in analogy to human arproteinase
Inhibitor, which is converted to pyroglutamic acid
during isolation without affecting the inhibitory pro-
perties. Amino terminal pyroglutamic acid is not
cleaved off by the Edman degradation, which there-
fore fails to detect an amino terminal residue. An
exactly similar observation has been reported for
human cti-proteinase inhibitor (10).
(iv) In immunoelectrophoresis only a single precipit-
ing arc occurred.
given proteinases and arproteinase inhibitor of man
and pig are of the same order of magnitude. The
extremely high kass value of the arproteinase inhibi-
tor-leukocyte elastase System of the pig suggests that,
äs in humans, arproteinase inhibitor is by far the
most likely candidate for interaction with liberated
lysosomal elastase. Therefore, in analogy to the Situ-
ation in humans, the elastase-arproteinase inhibitor
complex should be a suitable indicator of the inflam-
matory response in pigs.
The proteinases listed in table 3 indicate that the
Inhibition spectra of porcine arproteinase inhibitor Acknowledgement
and human arproteinase inhibitor (18) are very simi-
lar, even the association rate constants between the
This work was supported in part by Sonderforschungsbereich
SFB 0207 (projects LP 19 and 28) of the University of Munich.
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